Gastroenterology

Novo Nordisk has announced to enter into a collaboration with Dicerna’s RNAi platform to focus on metabolic and liver-related diseases. The companies will be focusing to advance the treatment landscape of the diseases such as non-alcoholic steatohepatitis (NASH), Type 2 diabetes and obesity. Nordisk will be investing an amount of USD 225 Million upfront along with hundreds of millions up to USD 357.5 million upon achieving the regulatory and commercialization milestones and targets. However, Dicerna will be funding the initial pre-clinical development phases of the products. Furthermore, Nordisk will be investing USD 50 million in Dicerna’s equity.   After the ...